title: Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.
abstract: Antibiotics excreted into the intestinal tract, such as broad-spectrum cephalosporins, disrupt the indigenous microflora, affect colonization resistance (CR), and promote intestinal colonization by resistant bacteria. We tested whether oral DAV131, a charcoal-based adsorbent, would prevent colonization by a cefotaxime (CTX)-resistant Klebsiella pneumoniae strain (PUG-2) in CTX-treated mice. Mice received CTX, saline, CTX and DAV131, or saline and DAV131 for 3 days before oral challenge with 10(6) CFU of PUG-2. The fecal CTX concentrations and counts of PUG-2 were assayed. Fecal CTX disappeared when DAV131 was given concomitantly with CTX (P < 0.05), and the area under the curve of PUG-2 fecal density was significantly reduced (P < 0.01). In conclusion, reducing intestinal antibiotic exposure with DAV131 may reduce colonization by resistant strains during treatment compared to treatment with CTX only. This might open new possibilities for decreasing the impact of antibiotics on the intestinal microbiota during treatments.
authors: EA 3964, University Paris Diderot, Paris, France.
authors: Nathalie
authors: N
authors: Grall
authors: Laurent
authors: L
authors: Massias
authors: Thu Thuy
authors: TT
authors: Nguyen
authors: Sakina
authors: S
authors: Sayah-Jeanne
authors: Nicolas
authors: N
authors: Ducrot
authors: Elisabeth
authors: E
authors: Chachaty
authors: Jean
authors: J
authors: de Gunzburg
authors: Antoine
authors: A
authors: Andremont
mesh_terms: D000284:Administration, Oral; D000327:Adsorption; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019540:Area Under Curve; D002439:Cefotaxime / Q000494:pharmacology*; D002606:Charcoal / Q000494:pharmacology*; D015169:Colony Count, Microbial; D004357:Drug Synergism; D005243:Feces / Q000382:microbiology; D005260:Female; D007422:Intestines / Q000187:drug effects* / Q000382:microbiology; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000254:growth & development; D051379:Mice; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D002606:Charcoal; D002439:Cefotaxime
references: Clin Infect Dis. 2001 Apr 15;32(8):1162-71
references: 11283805
references: Lancet. 2005 Feb 12-18;365(9459):579-87
references: 15708101
references: Int J Pharm. 2009 Sep 11;379(2):251-9
references: 19467304
references: Clin Infect Dis. 2004 Jul 15;39(2):219-26
references: 15307031
references: Br Med J. 1948 Oct 30;2(4582):769-82
references: 18890300
references: Antimicrob Agents Chemother. 1994 Mar;38(3):409-14
references: 8203832
references: Clin Infect Dis. 2009 Jan 1;48(1):1-12
references: 19035777
references: Antimicrob Agents Chemother. 2012 Sep;56(9):4973-5
references: 22751547
references: EMBO Rep. 2006 Jul;7(7):688-93
references: 16819463
references: J Antimicrob Chemother. 1992 Aug;30(2):234-6
references: 1399936
references: Clin Infect Dis. 2012 Mar 1;54(5):707-13
references: 22157322
references: Curr Opin Investig Drugs. 2009 Aug;10(8):838-44
references: 19649928
references: Eur J Pharm Sci. 2010 Oct 9;41(2):281-8
references: 20599502
references: FEMS Microbiol Rev. 2004 Oct;28(4):405-40
references: 15374659
references: Intensive Care Med. 2012 Nov;38(11):1769-78
references: 22893223